Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Jazz Pharmaceuticals clinical trials
The registry lists 223 studies whose lead sponsor is Jazz Pharmaceuticals or one of 6 companies grouped under it. 19 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.
Keep track of what changes. Save the Jazz Pharmaceuticals studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Jazz Pharmaceuticals.
- Jazz Pharmaceuticals173 studiesSame company
Something wrong?
- 33 studies →
- GW Pharmaceuticals Ltd7 studies →Acquired — became part of Jazz Pharmaceuticals, May 5, 2021 · source ↗
Something wrong?
- GW Research Ltd5 studies →Acquired — became part of Jazz Pharmaceuticals, May 5, 2021 · source ↗
Something wrong?
- 2 studies →
- Orphan Medical2 studies →Acquired — became part of Jazz Pharmaceuticals, Jun 24, 2005 · source ↗
Something wrong?
- Azur Pharma, Inc1 study →Acquired — became part of Jazz Pharmaceuticals, Jan 18, 2012 · source ↗
Something wrong?
Focus areas
Conditions Jazz Pharmaceuticals leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 223. Browse all 223 →
- Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System NeoplasmsRecruitingNCT04541082Phase 1
- A Study to Investigate the Effect of Gradual Titration to Optimize Cannabidiol Treatment in Adults With LGSNot yet recruitingNCT07728097Phase 4
- A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IHRecruitingNCT07625280Phase 3
- A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic EpilepsyRecruitingNCT07723963Phase 2/3
- Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During PregnancyRecruitingNCT06113237
- Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and ParagangliomaRecruitingNCT07282587Phase 2
- A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset SeizuresRecruitingNCT07233239Phase 1
- Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEANot yet recruitingNCT07780968
- A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast CancerRecruitingNCT07102381Phase 2
- A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLCRecruitingNCT07459634Phase 2
- Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract CancerRecruitingNCT06282575Phase 3
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP269 in Healthy Male and Female ParticipantsNot yet recruitingNCT07813663Phase 1
- A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 MeningiomaRecruitingNCT07533942Phase 2
- A Study to Evaluate the Safety and Efficacy of CBD-OS in Participants With DEENot yet recruitingNCT07723976Phase 3
- A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsRecruitingNCT06695845Phase 2
- ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)RecruitingNCT05580562Phase 3
- A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast CancerRecruitingNCT06435429Phase 3
- Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing SarcomaRecruitingNCT05734066Phase 1/2
- JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid TumorsRecruitingNCT06108050Phase 1
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy ParticipantsActive, not recruitingNCT07377539Phase 1
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Phase 3
- Phase 2a Study of ZW25 in Combination With Palbociclib Plus FulvestrantCompletedNCT04224272Phase 2
- A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815Active, not recruitingNCT05557045Phase 1
- A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and Functional Outcomes in Participants With Idiopathic Hypersomnia or NarcolepsyCompletedNCT05875974Phase 4
- Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral SolutionActive, not recruitingNCT05044819Phase 4
- A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing CancerCompletedNCT05027139Phase 1/2
- Long-Term Follow-Up of a Cohort of Participants Prescribed Epidyolex in France in a Real-life SettingActive, not recruitingNCT05772429
- Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALYActive, not recruitingNCT05485831
- A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis ComplexCompletedNCT05864846Phase 4
- A Switch Study From High-Sodium Oxybate to Xywav to Evaluate Changes in Blood Pressure in Participants With NarcolepsyCompletedNCT05869773Phase 4
- A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1TerminatedNCT06961266Phase 1
- To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)CompletedNCT04894591
- A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's DiseaseCompletedNCT05642442Phase 2
- VYxeoS Liposomal Italian Observational Study iN the Real PracticeCompletedNCT06143839
- Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled SeizuresTerminatedNCT04485104Phase 3
- A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract CancersCompletedNCT04466891Phase 2
- A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal CancerCompletedNCT03929666Phase 2
- Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline GliomasApproved for marketingNCT04617002
- ONC201 in Adults With Recurrent H3 K27M-mutant GliomaTerminatedNCT03295396Phase 2
- A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)CompletedNCT05122650Phase 2
- An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract CancerNo longer availableNCT04578444
- Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum DisorderCompletedNCT04745026Phase 2
- Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid TumorsTerminatedNCT05126433Phase 2
- ONC201 in Pediatric H3 K27M GliomasTerminatedNCT03416530Phase 1
Sponsor listed in the registry: Chimerix · First submitted before Chimerix became part of Jazz Pharmaceuticals
- Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic SeizuresTerminatedNCT05288283Phase 3
- A Study of JZP150 in Adults With Posttraumatic Stress DisorderCompletedNCT05178316Phase 2
- ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial CancerTerminatedNCT03485729Phase 2
Sponsor listed in the registry: Chimerix · First submitted before Chimerix became part of Jazz Pharmaceuticals
- Oral ONC201 in Adult Recurrent GlioblastomaTerminatedNCT02525692Phase 2
Sponsor listed in the registry: Chimerix · First submitted before Chimerix became part of Jazz Pharmaceuticals
- Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple SclerosisTerminatedNCT04984278Phase 3
- Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing CancersCompletedNCT02892123Phase 1